MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-18 pm EDT			5-day change	1st Jan Change
39.49 ^USD	-1.69%		-8.80%	-34.61%

Jun. 10	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from Both FDA and EMA on Path for the Phase 3 Program for the Nanobody Sonelokimab in Psoriatic Arthritis	CI
May. 07	MoonLake Immunotherapeutics Q1 Net Loss Widens	MT

MoonLake Immunotherapeutics Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 10, 2023 at 07:00 am EDT

MoonLake Immunotherapeutics reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 10.14 million. Basic loss per share from continuing operations was USD 0.23.
For the six months, net loss was USD 19.14 million. Basic loss per share from continuing operations was USD 0.46.

Latest news about MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from Both FDA and EMA on Path for the Phase 3 Program for the Nanobody Sonelokimab in Psoriatic Arthritis	Jun. 10	CI
MoonLake Immunotherapeutics Q1 Net Loss Widens	May. 07	MT
MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment	Apr. 10	MT
Goldman Sachs Initiates MoonLake Immunotherapeutics at Neutral With $62 Price Target	Apr. 02	MT
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	Mar. 11	DJ
HC Wainwright Adjusts Price Target on MoonLake Immunotherapeutics to $100 From $75, Maintains Buy Rating	Mar. 11	MT
MoonLake Immunotherapeutics Announces Significant Improvements with Nanobody Sonelokimab over 24 Weeks in Active Psoriatic Arthritis	Mar. 10	CI
Moonlake Immunotherapeutics to Present MIRA Trial Data of Nanobody Sonelokimab in Hidradenitis Suppurativa as A Late Breaker At the AAD Annual Meeting 2024	Mar. 04	CI
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,803,044, According to a Recent SEC Filing	Mar. 01	MT
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,540,710, According to a Recent SEC Filing	Mar. 01	MT
MoonLake Immunotherapeutics Shares Decline After Posting Q4 Loss	Feb. 29	MT
MoonLake Immunotherapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
MoonLake Immunotherapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
MoonLake Gains FDA, EMA Backing For Late-Stage Hidradenitis Suppurativa Trial	Feb. 26	MT
Moonlake Immunotherapeutics Insider Sold Shares Worth $1,208,418, According to a Recent SEC Filing	Feb. 23	MT
Wolfe Research Initiates MoonLake Immunotherapeutics With Outperform Rating, $77 Price Target	Feb. 15	MT
Moonlake Immunotherapeutics Insider Sold Shares Worth $5,917,368, According to a Recent SEC Filing	Dec. 21	MT
Stifel Adjusts Price Target on MoonLake Immunotherapeutics to $69 From $66, Maintains Buy Rating	Dec. 18	MT
Citigroup Starts MoonLake Immunotherapeutics With Buy Rating, $72 Price Target	Dec. 08	MT
Wedbush Raises MoonLake Immunotherapeutics' Price Target to $92 From $86, Maintains Outperform Rating	Nov. 16	MT
Guggenheim Adjusts MoonLake Immunotherapeutics' Price Target to $77 From $70, Maintains Buy Rating	Nov. 14	MT
MoonLake Immunotherapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
MoonLake Immunotherapeutics Says Phase 2 Trial of Nanobody Sonelokimab Met Primary Endpoint	Nov. 06	MT
MoonLake Immunotherapeutics Announces Landmark Phase 2 Results for Nanobody Sonelokimab in Active Psoriatic Arthritis	Nov. 05	CI

Chart MoonLake Immunotherapeutics

Duration

Period

More charts

Company Profile

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Sector

Biotechnology & Medical Research

Calendar

2024-06-24 - Stifel European Healthcare Summit

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

39.49 USD

Average target price

73.31 USD

Spread / Average Target

+85.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOONLAKE IMMUNOTHERAPEUTICS	-34.61%	2.48B
VERTEX PHARMACEUTICALS INCORPORATED	+14.84%	121B
REGENERON PHARMACEUTICALS, INC.	+18.31%	112B
ARGENX SE	+2.94%	22.72B
BIONTECH SE	-18.26%	20.82B
GENMAB A/S	-18.47%	16.66B
WUXI APPTEC CO., LTD.	-42.36%	16.36B
BEIGENE, LTD.	-14.23%	16.19B
NEUROCRINE BIOSCIENCES, INC.	-0.68%	13.17B
SAREPTA THERAPEUTICS, INC.	+21.87%	11.11B

Bio Therapeutic Drugs